Differentially expressed circular RNAs in peripheral blood mononuclear cells of PD patients

Stylianos Ravanidis, Anastasia Bougea, Dimitra Karampatsi, Nikolaos Papagiannakis, Matina Maniati, Leonidas Stefanis, Epaminondas Doxakis
doi: https://doi.org/10.1101/2020.11.14.20231779

ABSTRACT

Background New noninvasive and affordable molecular approaches that will complement current practices and increase the accuracy of PD diagnosis are urgently needed. CircRNAs are highly stable non-coding RNAs that accumulate with aging in neurons and are increasingly shown to regulate all aspects of neuronal development and function.

Objectives The aims of the present study were to identify differentially expressed circRNAs in PBMCs of idiopathic PD patients and explore the competing endogenous RNA networks affected.

Methods Eighty-seven circRNAs were initially selected based on relatively high gene expression in the human brain. Over half of these were readily detectable in PBMCs using RT-qPCR. Comparative expression analysis was then performed in PBMCs from sixty controls and sixty idiopathic subjects with PD.

Results Six circRNAs derived from MAPK9, HOMER1, SLAIN1, DOP1B, REPS1, and PSEN1 transcripts were significantly downregulated in PD patients. The classifier that best distinguished PD consisted of four circRNAs with an AUC of 0.84. CLIP-Seq data revealed that the RNA binding proteins bound by most of the deregulated circRNAs include the neurodegeneration-associated FUS, TDP43, FMR1 and ATXN2. MicroRNAs predicted to be sequestered by most deregulated circRNAs had the GOslim categories ‘Protein modification’, ‘Transcription factor activity’ and ‘Cytoskeletal protein binding’ mostly enriched.

Conclusions This is the first study that identifies circRNAs deregulated in the peripheral blood of PD patients. They may serve as diagnostic biomarkers and since they are highly expressed in the brain and are derived from genes with essential brain functions, they may also hint on the PD pathways affected.

INTRODUCTION

The diagnosis of PD is currently based on clinical diagnostic criteria and neuroimaging and is monitored by rating scales related to motor and non-motor features 1. Rating scales are frequently subjective and influenced by periodic fluctuations in symptoms and effective symptomatic therapies, while neuroimaging techniques, such as DAT-SPECT, offer a quantifiable measure of disease progression but are limited by practicality and costs 2. In addition, protein biomarkers, such as those based on alpha-synuclein (SNCA) and dopamine metabolic products have yielded mixed results, do not reflect disease progression and require an invasive lumbar puncture 3.

Circular RNAs (circRNAs) are a newly recognized class of single-stranded regulatory RNAs that are formed by head-to-tail splicing in which a downstream 5’ splice site is covalently connected to an upstream 3’ splice site of an RNA molecule. The result is an enclosed non-polyadenylated circular transcript 4-6. Due to the lack of free ends, that are normally targeted by 3’ and 5’ exoribonucleases, circRNAs are extremely stable with half-life of more than 48 h compared to approximately 6 h of linear transcripts 7, 8. There are different subtypes of circRNAs including exonic, intronic and exo-intronic. Exonic circRNAs are mostly localized in the cytoplasm where they act as sponges for microRNAs (miRNAs) and RNA-binding proteins (RBPs), thus inhibiting their interaction with mRNA targets 4, 9-11. In contrast, intronic or exo-intronic circRNAs are mostly localized in the nucleus and have few or no binding sites for miRNAs; instead they function to control transcription 12, 13. Interestingly, the co-transcriptional biogenesis of circRNAs has also been shown to reduce linear host mRNA levels and change downstream splice-site choice in some mRNAs 11, 14, 15.

CircRNAs are widely conserved and more abundant in the brain than in any other tissue 16 with many being expressed in an organ-specific manner, along with their host genes which are enriched with tissue-specific biological functions 17. For instance, brain circRNA host genes are enriched in neurotransmitter secretion, synaptic activities and neuron maturation 17. Importantly, however, they are regulated independently from their linear counterparts 16, 18 with 60% of CNS circRNAs being upregulated throughout development, especially during synaptogenesis, while only 2% of their linear isoforms show this tendency 17.

Recent studies revealed the deregulation of circRNAs in neurodegenerative diseases and neuropsychiatric disorders (reviewed in 19). Furthermore, several brain-enriched circRNAs have been associated with pathogenetic processes of neurodegeneration. For instance, CDR1as (ciRS-7), a highly abundant circRNA in the brain, is downregulated in the brain of patients with AD 20. This circRNA contains 63 binding sites for miR-7 and therefore it is acting as an efficient sponge for it 4. Importantly, critical proteins for the neurodegeneration processes such as the ubiquitin protein ligase A (UBE2A), which catalyses the proteolytic clearing of toxic amyloid peptides in AD, and SNCA, which accumulates in PD/AD, are both targets of miR-7 21, 22. More recently, another circRNA, circSLC8A1, was found to increase in the substantia nigra of individuals with PD and in cultured cells exposed to the oxidative stress-inducing agent paraquat 23. Importantly, circSLC8A1 carries seven binding sites for miR-128, an abundant and brain-restricted miRNA that governs neuronal excitability and motor behavior 24-27.

Peripheral blood mononuclear cells (PBMCs) inherit the same genetic information as brain cells and are armed with abundant signaling pathways that respond to pathological changes. Multiple studies have shown that genome-wide transcriptional and alternative splicing profiles in peripheral blood parallel changes in gene expression in the brain, reflecting broad molecular and cellular impairments 28-33. Therefore, PBMCs provide a powerful and minimally-invasive tool for the identification of novel targets for neurodegeneration research. Considering that circRNAs a) are abundant in the brain modulating gene expression en masse, b) are stable, c) do not get modified like proteins, hence levels directly correlate with activity and d) can be accurately quantified by routine and fast laboratory methods, such as RT-qPCR, suggests that they not only represent excellent candidate biomarkers but also important constituents of the pathophysiological processes implicated in neurological diseases. The purpose of this study was to identify differentially expressed brain-enriched circRNAs in PBMCs from patients with idiopathic PD (iPD) and pinpoint competing endogenous (ceRNA) networks.

MATERIAL AND METHODS

Figure 1 provides a schematic representation of the workflow.

Figure 1.
Figure 1. Schematic representation of the workflow.

Study population

The present study included 60 iPD patients and 60 healthy individuals in two separate cohorts. Patients were assessed with brain magnetic resonance imaging (MRI) or computed tomography (CT) and no relevant brain vascular lesions explaining the clinical phenotype were detected. The control group included spouses or unrelated companions of patients who had no known neurological disease, comorbidities or PD family history. Individuals with concurrent malignant tumours, psychiatric disorders, collagen diseases, endocrine and cardiovascular diseases, or infections were excluded from this study, since these conditions are expected to alter the expression profile of transcripts. Patients affected by atypical parkinsonism were also excluded. All patients and controls were recruited from the National and Kapodistrian University of Athens’ First Department of Neurology at Eginition hospital. PD was diagnosed by two neurologists according to Postuma et al., criteria 1. In all cases, essential demographic and clinical information, including the study questionnaire for motor and non-motor manifestations of the disease, rating scales [Hoehn & Yahr (H&Y) stage, mini-mental state examination (MMSE, cognitive impairment score <26 34), Unified Parkinson’s Disease Rating Scale part III (UPDRS III) in the on or off state] were collected and documented. The demographic and clinical features of patients and controls are summarized in Table 1. Levodopa equivalent daily dose (LEDD) was calculated for the patient group according to Tomlinson et al., criteria 35. The Eginition hospital and BRFAA ethics committees approved the study and all participants provided written consent.

View this table:
Table 1. Demographic and clinical profiles of healthy controls and PD patients.

Isolation of peripheral blood mononuclear cells

PBMCs were isolated from whole blood by employing density-gradient centrifugation using the Biocoll Separating Solution according to manufacturer’s instructions (Biochrom AG).

Total RNA extraction and RT-qPCR analysis

Total RNA extraction was performed using the RNAzol®-RT reagent according to manufacturer’s instructions (Molecular Research Center, MRC). To improve the yield of the small RNA fraction, a polyacryl carrier (PC152, MRC) was added during the extraction method. Reverse transcription reactions were performed in triplicate for every sample. Similarly, qPCR was performed in triplicate on the Roche Lightcycler® 96 using the SYBR FAST Universal 2X qPCR Master Mix from Kapa Biosystems. For the differential expression analysis, we selected only those circRNAs that were detected in PBMCs with a crossing threshold (Ct) value below 30, for improved detection accuracy. All primers span the splice junction. U6 and GAPDH were used as reference genes. The relative expression level of circRNAs was calculated using the 2-ΔΔCt method between age- and gender-matched counterparts. Primer sequences can be found in Suppl. Table 1.

CircRNA selection process

Eighty-seven circRNAs were carefully selected by cross-examining the data from three genome-wide surveys 4, 18, 36. We chose circRNAs that had high expression in the brain (Rybak-Wolf score above ∼1,000) and low or no expression in other tissues. The host gene expression was also taken into account in the selection process. Initially, based on GTEx portal expression data, circRNAs for which host transcripts were specifically expressed in the brain were selected. However, we found that many circRNAs derived from these transcripts were not readily detectable in PBMCs. We, therefore, widened the analysis to host transcripts that are brain- or at least cerebellum-enriched (i.e. not exclusively expressed in the brain). Last, we included six brain-abundant circRNAs deriving from host transcripts with low expression in the brain (UBXN7_circ_0001380, TMEM138_circ_0002058, ZNF292_circ_0004058, HAT1_circ_0008032, ZFAND6_circ_0000643, UIMC1_circ_0001558) and eight circRNAs that are hosted by brain-relevant transcripts that have been found deregulated in AD (CORO1C_circ_0000437, WDR78_circ_0006677, PHC3_circ_0001359, SLAIN2_circ_0126525) 37 and autism (FAM120A_circ_0001875, CSNK1G3_circ_0001522, VMP1_circ_0006508, SMARCA5_circ_0001445) 38. For the list of circRNAs analyzed see Suppl. Tables 1 and 2.

CircRNA target network

The interactions of the differentially expressed circRNAs with miRNAs and RBPs were identified by obtaining data from the Circular RNA Interactome (CircInteractome) and Interactional Database of Cancer-Specific CircRNAs (IDCSC) databases, respectively 39, 40. CircInteractome utilizes the TargetScan algorithm to predict microRNA response elements (MREs, ie miRNA-binding sites) while IDCSC hosts circRNA cross-linking immunoprecipitation (CLIP)-Seq data for the different RBPs extracted from StarBase database 41. The circRNA-miRNA and circRNA-RBP interactomes were then manually curated using the Cytoscape v.3.8.0 platform.

miRNA pathway analysis

The DIANA mirPath v.3 software suite was used to identify miRNA-regulated pathways. This software renders possible the functional annotation of miRNAs using standard hypergeometric distributions, unbiased empirical distributions and meta-analysis statistics 42. Here, predicted targets from DIANA microT-CDS algorithm with high quality experimentally supported interactions were used to identify KEGG molecular pathways, as well as GO terms targeted by each miRNA. The combinatorial effect of deregulated miRNAs was identified by simultaneously selecting multiple miRNAs in the software. The default values (p-value threshold 0.05, microT-CDS threshold 0.8, FDR correction option ticked) were used for the analysis.

Statistical analysis

Statistical analysis was performed using GraphPad PRISM v5.0 and R v3.5.3. All data underwent a normality test (Shapiro–Wilk), and were found to be non-normally distributed. As a result, all circRNA data underwent a logarithmic transformation (with base 2), in order to better approximate the normal distribution. The parametric t-test was used to observe differences between healthy controls and PD patients. We applied the Benjamini – Hochberg false discovery rate correction in the resulting p-values to account for the multiple number of tests. Spearman’s method with Bonferroni correction for multiple comparisons was used to correlate circRNA expression levels with participants’ demographic and clinical characteristics (p-value threshold 0.0005).

To assess the possibility that sex is a confounding factor, the two-way ANOVA model was applied to the log-transformed data (normally distributed) with sex as an additional factor. No difference in the circRNAs that were statistically significant was found.

Receiver operating characteristic (ROC) curves were constructed and the area under the curve (AUC) was calculated to evaluate the predictive sensitivity and specificity of PBMC circRNAs for PD diagnosis. The cutoff value for the ROC analysis was determined using the Youden Index. Data are presented as means ± SEM. circRNA selection was based on the stepwise removal approach. A logistic regression statistical model containing all available circRNAs as independent variables and PD status as the dependent variable was built. Then, the circRNAs with the least contribution in the model (as determined by an F test) were removed. This process continued until no further removals were possible.

Data availability

The datasets analysed during the current study are all available from the corresponding author on request.

RESULTS

circRNAs are differentially expressed in PBMCs of idiopathic PD patients

The demographic and clinical characteristics of 60 healthy controls and 60 iPD patients are summarized in Table 1. The mean age of 64.5 and the sex ratio were the same for both groups. The disease duration for the PD group was 4.8±0.55 years and the MMSE score 27.5±0.56. Initially, RT-qPCR was employed to detect plasma levels of 32 circRNAs that are highly-expressed by brain cells. It was anticipated that a sufficient quantity of brain-derived circRNAs would find its way into the plasma. However, only two circRNAs, RMST (at Ct 29) and PSD3 (at Ct 28), were detected. Using the same amount of RNA, this time extracted from human brain tissue, it was revealed that all circRNAs were readily detectable with an average Ct value of 26, demonstrating that all primer pairs were functional (data not shown). This indicated that brain-enriched circRNAs are not as abundant as brain-enriched miRNAs (average Ct value of 17.5 for 21 brain-enriched miRNAs in the same human brain total RNA) and are not circulating in appreciable amount in the blood (average Ct value for the corresponding miRNAs in the plasma is 25) 43.

Based on previous studies showing that genome-wide transcriptional and alternative splicing profiles in peripheral blood cells parallel changes in gene expression in the brain, the levels of circRNAs were next assessed in PBMCs. We increased the number of primer sets to 87 and found that 48 were detected with a Ct value below 30, safeguarding accurate and reproducible detection. These circRNAs were then analyzed for differential expression in healthy control and iPD patient samples (Suppl. Table 3).

Following multiple comparison adjustment, six circRNAs were significantly altered in the PBMCs obtained from PD patients compared to healthy controls. MAPK9_circ_0001566, HOMER1_circ_0006916, SLAIN1_circ_0000497, DOP1B_circ_0001187, RESP1_circ_0004368, and PSEN1_circ_0003848 were all downregulated in the PD cohort (Fig. 2 and Suppl. Table 3). The swarm plots for the 42 circRNAs whose relative expression was not significantly altered in the PBMCs of idiopathic PD patients are shown in Supplemental Fig 1.

Figure 2.
Figure 2. Swarm plots of deregulated circRNAs relative expression in the PBMCs of control and idiopathic PD cohorts.

Mean levels +/- SEM are included below each graph. Graphs demonstrate relative expression of log-transformed data. Unpaired t-test was used to determine the significance of differences between the two groups. *p<0.05, **p<0.01, ***p<0.001.

Association between circRNA levels and clinical features, age or sex

Spearman correlation test was used to relate circRNA levels to iPD patients’ clinical features. We found no correlation between age-at-onset, disease duration, UPDRS III, MMSE, LEDD, H&Y or patients’ on/off state and circRNA levels (Suppl. Table 4 and data not shown). Finally, correcting clinical scores with LEDD did not reveal any more associations (data not shown). In addition, there was no significant correlation between circRNA expression and age or sex in either healthy controls or PD patients.

Discriminant Analysis

To evaluate the utility of PBMC circRNA levels in discriminating subjects with iPD from healthy controls, ROC curve analysis was performed. The diagnostic sensitivity and specificity of a four circRNA panel (SLAIN1_circ_0000497, SLAIN2_circ_0126525, ANKRD12_circ_0000826, and PSEN1_circ_0003848) were 75.3% (62.1-85.2%) and 78% (65.8-88%), respectively, and the AUC was 0.84 (Fig. 3).

Figure 3.
Figure 3. The receiver operating characteristic (ROC) curve analysis for discriminating idiopathic PD from healthy control subjects.

ROC curve of four circRNAs (MAPK9_circ_0001566, SLAIN1_circ_0000497, SLAIN2_circ_0126525, and PSEN1_circ_0003848) differentiate iPD from HC cases.

CeRNA networks

CircRNAs can act as miRNA and RBP sponges for regulating gene expression. To explore the functional role of the deregulated circRNAs we identified all their miRNA and RBP targets. Multiple miRNA binding sites are predicted for each circRNA, with SLAIN1_circ_0000497 and MAPK9_circ_0001566 having the most of MREs (38 and 24, respectively) (Fig. 4A).

Figure 4.
Figure 4. CircRNA target networks.

Diagrams show (A) the predicted miRNAs and (B) the CLIP-Seq identified RBPs that bind to differentially expressed circRNAs.

Interestingly, five miRNAs were predicted to be sponged by half or more of the deregulated PD circRNAs. miR-526b and miR-659 are the top targets, sequestered by four deregulated PD circRNAs (Fig. 4A). Fig. 4B shows the deregulated circRNA-RBP network. Like for miRNAs, CLIP-Seq data obtained from StarBase database revealed that the deregulated circRNAs have multiple RBP binding sites. MAPK9_circ_0001566 and HOMER1_circ_0006916 host the most of these sites with 60 and 49 sites, respectively. Interestingly, 29 RBPs were sequestered by four or more deregulated circRNAs.

CircRNA-miRNA pathway analysis

In order to explore the biological pathways affected by the five miRNAs (miR-516b-5p, miR-526b-5p, miR-578, miR-659-3p, and miR-1197) mostly sequestered by three or more of the deregulated circRNAs, the DIANA mirPath v3 tool was used to align miRNA predicted targets with KEGG pathways and GOslim categories. A Priori gene union analysis of deregulated miRNA targets revealed fourteen KEGG categories as significantly enriched; they included ‘Thyroid hormone signaling pathway’ (p< 0.0015, 24 genes), ‘Regulation of actin cytoskeleton’ (p< 0.015, 42 genes) ‘Phosphatidylinositol signaling pathway’ (p< 0.016, 16 genes), ‘MAPK signaling pathway’ (p< 0.016, 46 genes) and ‘FoxO signaling pathway’ (p< 0.016, 26 genes) (Suppl. Table 5A). Similar findings were obtained using a Posteriori analysis (Suppl. Fig. 2A). Thirty-nine GOslim categories that are controlled by the gene union of the deregulated miRNA targets were enriched following a Priori analysis; these included ‘Cellular protein modification’ (p< 3.93E-19, 283 genes), ‘Nucleic acid binding transcription factor activity’ (p< 7.74E-07, 112 genes), ‘Cytoskeletal protein binding’ (p< 3.91E-09, 102 genes) ‘Cell death’ (p< 7.91E-08, 112 genes), ‘RNA binding’ (p< 6.93E-07, 207 genes) and ‘Response to stress’ (p< 3.72E-05, 225 genes) (Suppl. Table 5B). Similar findings were obtained using a Posteriori analysis (Suppl. Fig. 2B).

DISCUSSION

We profiled brain-enriched circRNAs in peripheral blood from controls and patients with PD using a RT-qPCR -based approach for three reasons. First, primers could be designed to span the splicing junction which guarantees that only message from the circRNA is amplified. Second, RT-qPCR is the most sensitive method to accurately determine expression changes between cohorts; the alternative microarray approach is prone to errors at multiple levels and nearly always requires a follow up RT-qPCR-based analysis to validate findings. Third, we probed circRNAs that are abundantly expressed in the brain; in this way, we could identify differentially expressed or spliced circRNAs that are more likely associated with the neurological processes of PD.

Insights into the differentially expressed circRNA genes

We initiated our study with 87 brain-enriched circRNAs from which over half were confidently detected in PBMCs. From these circRNAs, six were differentially expressed in PD with a 17% decrease on average from healthy controls levels. These changes may appear subtle but depending on the circRNA baseline expression levels and considering the relative importance of their multiple targets (transcription factors, RBPs, and miRNAs) as well as the added-up deregulation of the common targets, the biological outcome is expected to be significant.

It has been observed that the biological role of host transcripts reflects on the function of the circRNAs 17. We found that the host transcripts of the differentially-expressed circRNAs are not exclusive to brain pathways; rather, they are house-keeping genes, whose functions are best characterized in the CNS as they are essential for neuronal homeostasis. A brief bibliographical overview of their properties is described below.

Hsa_circ_0001566 is hosted by the mitogen-activated protein kinase 9 (MAPK9) gene. MAPK9/JNK2 is a member of the c-Jun n-terminal kinase 1-3 family robustly activated by environmental stresses, including the PD-related neurotoxins lipopolysaccharides (LPS), MPTP and 6-hydroxydopamine (6-OHDA) to mediate neuronal degeneration 44. It is indispensable during brain development for neuronal migration, axonal sprouting and guidance, as well as neuronal survival 45. Hsa_circ_0006916 is hosted by the homer scaffold protein 1 (HOMER1) gene. HOMER1 is a member of Homer 1-3 family constituting important scaffold proteins at the postsynaptic density that associate with a large number of Ca2+-handling proteins, including channels, receptors, and shank scaffolding proteins to regulate intracellular Ca2+ homeostasis 46. An SNP in the promoter of HOMER1 has been associated with psychotic symptoms in PD 47. Further, circHomer1a is reduced in the prefrontal cortex of patients with schizophrenia and bipolar disorder, where it modulates the alternative splicing of mRNA transcripts involved in synaptic plasticity and psychiatric disease 11. Hsa_circ_0000497 is hosted by the SLAIN motif family member 1 (SLAIN1) gene. SLAIN1 and 2 are microtubule-associated proteins that promote persistent microtubule growth by recruiting the microtubule polymerase ch-TOG to microtubule plus-ends and thus they are important for axon elongation in developing neurons 48. Recently, SLAIN1 was identified as a candidate gene for intellectual disability 49. Hsa_circ_0001187 is hosted by the DOP1 leucine zipper like protein B (DOP1B) gene. DOP1B/ DOPEY2/ C21orf5 and its ortholog DOP1A interact with partner MON2 to retrograde transport endosomes from the TGN to the Golgi 50, 51. DOP1B is a candidate gene for mental retardation in Down syndrome 52, 53 and copy number variations (CNVs) have been observed in AD 54, 55. Hsa_circ_0004368 is hosted by the RALBP1 associated eps domain containing 1 (REPS1) gene. REPS1 is a signaling and endocytosis adaptor that interacts with adaptor Intersectin 1 (ITSN1) in clathrin-coated pits and Amphiphysin 1 (AMPH) at the surface of synaptic vesicles 56. Mutations in REPS1 are associated with neurodegeneration with brain iron accumulation (NBIA) in the basal ganglia 57. Hsa_circ_0003848 is hosted by the presenilin 1 (PSEN1) gene. PSEN1 and its paralog PSEN2 are the endoprotease subunits of the gamma-secretase complex that catalyses the intramembrane cleavage of integral membrane proteins such as Notch receptors and amyloid-beta precursor protein (APP). Mutations in either gene cause early-onset AD 58 and α-synuclein accumulation in LB in these patients 59. Besides their established role in mediating the formation of Aβ peptide, more recently mutant PS1 has been shown to impair numerous cellular functions such as calcium flux, organization of proteins in different compartments, and protein turnover via vacuolar metabolism 60. Interestingly, a novel PSEN1 mutation was recently identified as the likely cause for early-onset Parkinsonism 61.

Correlation between circRNA levels and demographics

There was no significant correlation between the differential expression of a particular circRNA and clinical or demographic measures. Combined interactions with age and sex did not also appear to affect circRNA levels. These findings reinforce current knowledge that the etiology of PD is complex involving a mix of genetic and environmental influences on ageing brain. Similar findings have been observed in miRNA studies 62. Further, a pool of four circRNAs discriminated subject with PD from controls with an AUC of 0.84.

CircRNA-RBP and circRNA-miR interactions

In silico approaches were utilized to identify potential biological roles for the deregulated circRNAs by identifying the RBPs and miRNAs that are sequestered preferentially by them. Since the circRNAs were all downregulated, it indicates that target RBP and miRNA functions will be enhanced in PD. The circRNA-RBP network which is based on experimental CLIPS-seq data revealed that 29 RBPs were bound by four or more deregulated circRNAs. Importantly, several of these RBPs are implicated in familial neurodegeneration including Fragile X Mental Retardation Protein 1 (FMR1, Fragile X syndrome and associated disorders), Ataxin 2 (ATXN2, Spinocerebellar ataxia 2, late-onset PD), Fused in Sarcoma (FUS) and TAR DNA binding protein (TARDBP/TDP43) (Amyotrophic lateral sclerosis, Frontotemporal dementia) 63-72.

The circRNA-miRNA network revealed five miRNAs that were predicted to be sponged by at least three downregulated PD circRNAs. miR-659-3p is of particular interest as it targets progranulin (PGRN), a neuroprotective and anti-inflammatory protein implicated in FTD 73-77. To explore the molecular pathways controlled by the five miRNAs, in silico analysis of KEGG pathways and GOslim terms was performed. KEGG categories revealed multiple signaling pathways (Thyroid hormone, Phosphatidylinositol, MAPK, FoxO) implicated in neuronal survival and plasticity and ‘Regulation of actin cytoskeleton’ which is central to pre- and postsynaptic assembly as over-represented 78-81. GOslim analysis revealed ‘Cellular protein modification’, ‘Nucleic acid binding transcription factor activity’, ‘Cytoskeletal protein binding’, ‘Cell death’, and ‘Response to stress’ as overrepresented among the biological processes affected. ‘Cellular protein modifications’ such as phosphorylation, ubiquitination, truncation, acetylation, nitration and sumoylation of PD-linked proteins have emerged as important modulators of pathogenic mechanisms in PD 82, 83. ‘Transcription factor’ changes indicate that there is not only misexpression at the mRNA translation level by miRNA deregulation, but that there exists a second wave of en masse deregulation involving transcription-mediated changes. Finally, deregulation of fine cytoskeletal dynamics is expected to impair trafficking and intracellular signaling pathways and has been recognized as a key insult in the pathogenesis of multiple neurodegenerative diseases including PD 84, 85.

Conclusions

We performed an RT-qPCR-based analysis on RNA extracted from PBMC cells from a cohort of patients with PD and matched controls to identify deregulated circRNAs. The circRNAs investigated are highly-expressed in the human brain. This is the first study of its kind in PD. The measurement of four out of six downregulated circRNAs provided reasonable sensitivity and specificity for PD in this discovery cohort. The circRNAs found deregulated form a robust set of brain-associated circRNAs, that can now be further evaluated, along with other measures, as diagnostic and possible therapeutic targets for PD. In silico analysis provided a comprehensive guide of the pathways and processes they control, shedding light on their potential biological role. The impact of these findings will now await further exploration.

Data Availability

The datasets analysed during the current study are all available from the corresponding author on request.

AUTHORS’ ROLES

Conceived the study: ED. Neurologically examined patients: AB, NP, LS. Peripheral blood processing: MM. Differential expression analysis: SR, DK, ED. Analyzed data: SR, NP, ED. Bioinformatics analyses: ED. Wrote the manuscript: ED. All authors read, edited and approved the final manuscript.

FINANCIAL DISCLOSURES

Stylianos Ravanidis: SR is a postdoctoral researcher at BRFAA. No Disclosures.

Anastasia Bougea: AB is a neurology resident at Eginition Hospital. No Disclosures.

Dimitra Karampatsi: DK is a former MSc student at BRFAA. No Disclosures.

Nikolaos Papagiannakis: NP is a neurology resident at Eginition Hospital. No Disclosures.

Matina Maniati: MM is a technician at BRFAA. No Disclosures.

Leonidas Stefanis: Leonidas Stefanis is employed by the National and Kapodistrian University of Athens and the Biomedical Research Foundation of the Academy of Athens. He has the following active grants: Fondation Sante research grant, a Michael J. Fox Foundation grant as a collaborator and an ELIDEK grant. He has served on an Advisory Board for Abbvie, Novartis and Roche and has received honoraria from Abbvie and Sanofi.

Epaminondas Doxakis: ED is employed by BRFAA. He has one active MJFF research grant.

SUPPLEMENTAL FIGURES

Supplemental Figure 1.
Supplemental Figure 1.
Supplemental Figure 1. Swarm plots for the 42 circRNAs whose relative expression is not significantly altered in the PBMCs of idiopathic PD patients.

Mean levels +/- SEM are included below each graph. Graphs demonstrate relative expression of log-transformed data. Unpaired t-test was used to determine the significance of differences between the two groups. *p<0.05, **p<0.01, ***p<0.001.

Supplemental Figure 2.
Supplemental Figure 2. KEGG and GOslim classifications of the circRNA-miRNA target genes.

(A) KEGG and (B) GOslim categories union of the RNA targets of the five miRNAs sequestered by three or more of the deregulated PD circRNAs (miR-516b-5p, miR-526b-5p, miR-578, miR-659-3p, miR-1197). They were prepared using the DIANA-miRPath v3.0 interface using default values (p-value threshold 0.05, microT-CDS threshold 0.8).

SUPPLEMENTAL TABLES

View this table:
Supplemental Table 1. Primer sequences used for real-time PCR
View this table:
Supplemental Table 2. List of 39 circRNAs not detected in PBMCs
View this table:
Supplemental Table 3. Basic characteristics and comparative PBMC circRNA expression in idiopathic PD patients and healthy controls.

CircRNA size and expression in the brain as well as host transcript expression in the body. Means with their respective standard deviation (std) for both groups are shown. Statistically significant differences in comparison to healthy controls (unpaired t-test) are highlighted in grey. Multiple comparison analysis (adjusted P values) calculated according to Benjamini-Hochberg false discovery rate method.

View this table:
Supplemental Table 4. Correlation between relative circRNA expression and sex, age, age-at-onset, PD duration, HY, UPDRS and MMSE scores and LEDD of PD patients.
View this table:
Significance Supplemental Table 5. KEGG and GOslim categories that are mostly deregulated in idiopathic PD.

Gene union of the targets of the five miRNAs (miR-516b-5p, miR-526b-5p, miR-578, miR-659-3p, miR-1197) sequestered by half or more of the deregulated PD circRNAs in PD versus (A) KEGG and (B) GOslim categories created by the DIANA-miRPath v3.0 interface using default values (p-value threshold 0.05, microT-CDS threshold 0.8).

ACKNOWLEDGMENTS

The authors are grateful to patients, relatives, and volunteer healthy controls for their participation in this study. This research was financed by Greece and European Union (European Social Fund- ESF) through the Operational Program «Human Resources Development, Education and Lifelong Learning 2014-2020» in the context of the project “Development of diagnostic biomarker tests for Parkinson’s disease” (MIS 5049385). It was also co-financed by the action “Precision medicine Hellenic network in genetic neurodegenerative diseases” (2018ΣE01300001) of the Hellenic public investments program of GSRT and the Michael J. Fox Foundation for Parkinson’s Research (Grant ID 13353).

ABBREVIATIONS

6-OHDA
6-hydroxydopamine
ANCOVA
analysis of covariance
ANOVA
analysis of variance
APP
amyloid-beta precursor protein
AUC
area under the curve
circRNA
circular RNA
CT
computed tomography
DOP1B
DOP1 leucine zipper like protein
FTD
Frontotemporal dementia
GO
gene ontology
H&Y
Hoehn & Yahr
HC
healthy control
HDAC
histone deacetylase
HOMER1
homer scaffold protein 1
hsa
homo sapiens
iPD
idiopathic PD
KEGG
Kyoto encyclopedia of genes and genomes
LEDD
Levodopa equivalent daily dose
LPS
lipopolysaccharides
MAPK9
mitogen-activated protein kinase 9
MMSE
Mini Mental State Examination
MRI
magnetic resonance imaging
NBIA
neurodegeneration with brain iron accumulation
PD
Parkinson’s disease
PSEN1
presenilin 1
REPS1
RALBP1 associated eps domain containing 1
SNCA
alpha-synuclein
SLAIN1
SLAIN motif family member
UPDRS
unified Parkinson’s disease rating scale
TARDBP
TAR DNA Binding Protein
UTR
untranslated region

REFERENCES

  1. 1.↵
    Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Movement disorders : official journal of the Movement Disorder Society 2015;30(12):1591–1601.
    OpenUrl
  2. 2.↵
    Bhidayasiri R, Martinez-Martin P. Clinical Assessments in Parkinson’s Disease: Scales and Monitoring. International review of neurobiology 2017;132:129–182.
    OpenUrl
  3. 3.↵
    Miller DB, O’Callaghan JP. Biomarkers of Parkinson’s disease: present and future. Metabolism: clinical and experimental 2015;64(3 Suppl 1):S40–46.
    OpenUrl
  4. 4.↵
    Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013;495(7441):333–338.
    OpenUrlCrossRefPubMed
  5. 5.
    Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PloS one 2012;7(2):e30733.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Zaphiropoulos PG. Circular RNAs from transcripts of the rat cytochrome P450 2C24 gene: correlation with exon skipping. Proceedings of the National Academy of Sciences of the United States of America 1996;93(13):6536–6541.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. Rna 2013;19(2):141–157.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Schwanhausser B, Busse D, Li N, et al. Global quantification of mammalian gene expression control. Nature 2011;473(7347):337–342.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Abdelmohsen K, Panda AC, Munk R, et al. Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA biology 2017;14(3):361–369.
    OpenUrl
  10. 10.
    Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature 2013;495(7441):384–388.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    Zimmerman AJ, Hafez AK, Amoah SK, et al. A psychiatric disease-related circular RNA controls synaptic gene expression and cognition. Molecular psychiatry 2020.
  12. 12.↵
    Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nature structural & molecular biology 2015;22(3):256–264.
    OpenUrl
  13. 13.↵
    Zhang Y, Zhang XO, Chen T, et al. Circular intronic long noncoding RNAs. Molecular cell 2013;51(6):792–806.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Ashwal-Fluss R, Meyer M, Pamudurti NR, et al. circRNA biogenesis competes with pre-mRNA splicing. Molecular cell 2014;56(1):55–66.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    Koh W, Gonzalez V, Natarajan S, Carter R, Brown PO, Gawad C. Dynamic ASXL1 Exon Skipping and Alternative Circular Splicing in Single Human Cells. PloS one 2016;11(10):e0164085.
    OpenUrl
  16. 16.↵
    You X, Vlatkovic I, Babic A, et al. Neural circular RNAs are derived from synaptic genes and regulated by development and plasticity. Nature neuroscience 2015;18(4):603–610.
    OpenUrlCrossRefPubMed
  17. 17.↵
    Mahmoudi E, Cairns MJ. Circular RNAs are temporospatially regulated throughout development and ageing in the rat. Scientific reports 2019;9(1):2564.
    OpenUrl
  18. 18.↵
    Rybak-Wolf A, Stottmeister C, Glazar P, et al. Circular RNAs in the Mammalian Brain Are Highly Abundant, Conserved, and Dynamically Expressed. Molecular cell 2015;58(5):870–885.
    OpenUrlCrossRefPubMed
  19. 19.↵
    Mehta SL, Dempsey RJ, Vemuganti R. Role of circular RNAs in brain development and CNS diseases. Progress in neurobiology 2020;186:101746.
    OpenUrlCrossRef
  20. 20.↵
    Lukiw WJ. Circular RNA (circRNA) in Alzheimer’s disease (AD). Frontiers in genetics 2013;4:307.
    OpenUrl
  21. 21.↵
    Doxakis E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-The Journal of biological chemistry 2010;285(17):12726–12734.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    Zhao Y, Alexandrov PN, Jaber V, Lukiw WJ. Deficiency in the Ubiquitin Conjugating Enzyme UBE2A in Alzheimer’s Disease (AD) is Linked to Deficits in a Natural Circular miRNA-7 Sponge (circRNA; ciRS-7). Genes 2016;7(12).
  23. 23.↵
    Hanan M, Simchovitz A, Yayon N, et al. A Parkinson’s disease CircRNAs Resource reveals a link between circSLC8A1 and oxidative stress. EMBO molecular medicine 2020:e11942.
  24. 24.↵
    Paschou M, Doxakis E. Neurofibromin 1 Is a miRNA Target in Neurons. PloS one 2012;7(10):e46773.
    OpenUrlCrossRefPubMed
  25. 25.
    Paschou M, Maier L, Papazafiri P, et al. Neuronal microRNAs modulate TREK two-pore domain K(+) channel expression and current density. RNA biology 2020;17(5):651–662.
    OpenUrl
  26. 26.
    Tan CL, Plotkin JL, Veno MT, et al. MicroRNA-128 governs neuronal excitability and motor behavior in mice. Science 2013;342(6163):1254–1258.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    Zhang W, Kim PJ, Chen Z, et al. MiRNA-128 regulates the proliferation and neurogenesis of neural precursors by targeting PCM1 in the developing cortex. eLife 2016;5.
  28. 28.↵
    Iturria-Medina Y, Khan AF, Adewale Q, Shirazi AH, Alzheimer’s Disease Neuroimaging I. Blood and brain gene expression trajectories mirror neuropathology and clinical deterioration in neurodegeneration. Brain : a journal of neurology 2020;143(2):661–673.
    OpenUrl
  29. 29.
    Naughton BJ, Duncan FJ, Murrey DA, et al. Blood genome-wide transcriptional profiles reflect broad molecular impairments and strong blood-brain links in Alzheimer’s disease. Journal of Alzheimer’s disease : JAD 2015;43(1):93–108.
    OpenUrl
  30. 30.
    Pinho R, Guedes LC, Soreq L, et al. Gene Expression Differences in Peripheral Blood of Parkinson’s Disease Patients with Distinct Progression Profiles. PloS one 2016;11(6):e0157852.
    OpenUrlCrossRefPubMed
  31. 31.
    Soreq L, Bergman H, Israel Z, Soreq H. Exon arrays reveal alternative splicing aberrations in Parkinson’s disease leukocytes. Neuro-degenerative diseases 2012;10(1-4):203–206.
    OpenUrl
  32. 32.
    van Heerden JH, Conesa A, Stein DJ, Montaner D, Russell V, Illing N. Parallel changes in gene expression in peripheral blood mononuclear cells and the brain after maternal separation in the mouse. BMC research notes 2009;2:195.
    OpenUrl
  33. 33.↵
    Soreq L, Salomonis N, Bronstein M, et al. Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes. Frontiers in molecular neuroscience 2013;6:10.
    OpenUrl
  34. 34.↵
    Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Movement disorders : official journal of the Movement Disorder Society 2007;22(16):2314–2324.
    OpenUrl
  35. 35.↵
    Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Movement disorders : official journal of the Movement Disorder Society 2010;25(15):2649–2653.
    OpenUrl
  36. 36.↵
    Maass PG, Glazar P, Memczak S, et al. A map of human circular RNAs in clinically relevant tissues. Journal of molecular medicine 2017;95(11):1179–1189.
    OpenUrl
  37. 37.↵
    Dube U, Del-Aguila JL, Li Z, et al. An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. Nature neuroscience 2019;22(11):1903–1912.
    OpenUrl
  38. 38.↵
    Gokool A, Anwar F, Voineagu I. The Landscape of Circular RNA Expression in the Human Brain. Biological psychiatry 2020;87(3):294–304.
    OpenUrlCrossRef
  39. 39.↵
    Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. CircInteractome: A web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA biology 2016;13(1):34–42.
    OpenUrl
  40. 40.↵
    Xia S, Feng J, Chen K, et al. CSCD: a database for cancer-specific circular RNAs. Nucleic acids research 2018;46(D1):D925–D929.
    OpenUrlCrossRefPubMed
  41. 41.↵
    Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic acids research 2014;42(Database issue):D92–97.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    Vlachos IS, Zagganas K, Paraskevopoulou MD, et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic acids research 2015;43(W1):W460–466.
    OpenUrlCrossRefPubMed
  43. 43.↵
    Ravanidis S, Bougea A, Papagiannakis N, et al. Circulating Brain-enriched MicroRNAs for detection and discrimination of idiopathic and genetic Parkinson’s disease. Movement disorders : official journal of the Movement Disorder Society 2020;35(3):457–467.
    OpenUrl
  44. 44.↵
    Dzamko N, Zhou J, Huang Y, Halliday GM. Parkinson’s disease-implicated kinases in the brain; insights into disease pathogenesis. Frontiers in molecular neuroscience 2014;7:57.
    OpenUrl
  45. 45.↵
    Waetzig V, Zhao Y, Herdegen T. The bright side of JNKs-Multitalented mediators in neuronal sprouting, brain development and nerve fiber regeneration. Progress in neurobiology 2006;80(2):84–97.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    Jardin I, Lopez JJ, Berna-Erro A, Salido GM, Rosado JA. Homer proteins in Ca(2)(+) entry. IUBMB life 2013;65(6):497–504.
    OpenUrl
  47. 47.↵
    De Luca V, Annesi G, De Marco EV, et al. HOMER1 promoter analysis in Parkinson’s disease: association study with psychotic symptoms. Neuropsychobiology 2009;59(4):239–245.
    OpenUrlPubMed
  48. 48.↵
    van der Vaart B, Franker MA, Kuijpers M, et al. Microtubule plus-end tracking proteins SLAIN1/2 and ch-TOG promote axonal development. The Journal of neuroscience : the official journal of the Society for Neuroscience 2012;32(42):14722–14728.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    Harripaul R, Vasli N, Mikhailov A, et al. Mapping autosomal recessive intellectual disability: combined microarray and exome sequencing identifies 26 novel candidate genes in 192 consanguineous families. Molecular psychiatry 2018;23(4):973–984.
    OpenUrl
  50. 50.↵
    McGough IJ, de Groot REA, Jellett AP, et al. SNX3-retromer requires an evolutionary conserved MON2:DOPEY2:ATP9A complex to mediate Wntless sorting and Wnt secretion. Nature communications 2018;9(1):3737.
    OpenUrl
  51. 51.↵
    Zhao SB, Dean N, Gao XD, Fujita M. MON2 Guides Wntless Transport to the Golgi through Recycling Endosomes. Cell structure and function 2020;45(1):77–92.
    OpenUrl
  52. 52.↵
    Lopes C, Chettouh Z, Delabar JM, Rachidi M. The differentially expressed C21orf5 gene in the medial temporal-lobe system could play a role in mental retardation in Down syndrome and transgenic mice. Biochemical and biophysical research communications 2003;305(4):915–924.
    OpenUrlPubMed
  53. 53.↵
    Rachidi M, Delezoide AL, Delabar JM, Lopes C. A quantitative assessment of gene expression (QAGE) reveals differential overexpression of DOPEY2, a candidate gene for mental retardation, in Down syndrome brain regions. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 2009;27(4):393–398.
    OpenUrl
  54. 54.↵
    Swaminathan S, Huentelman MJ, Corneveaux JJ, et al. Analysis of copy number variation in Alzheimer’s disease in a cohort of clinically characterized and neuropathologically verified individuals. PloS one 2012;7(12):e50640.
    OpenUrlCrossRefPubMed
  55. 55.↵
    Swaminathan S, Shen L, Kim S, et al. Analysis of copy number variation in Alzheimer’s disease: the NIALOAD/ NCRAD Family Study. Current Alzheimer research 2012;9(7):801–814.
    OpenUrl
  56. 56.↵
    Dergai O, Novokhatska O, Dergai M, et al. Intersectin 1 forms complexes with SGIP1 and Reps1 in clathrin-coated pits. Biochemical and biophysical research communications 2010;402(2):408–413.
    OpenUrlCrossRefPubMed
  57. 57.↵
    Drecourt A, Babdor J, Dussiot M, et al. Impaired Transferrin Receptor Palmitoylation and Recycling in Neurodegeneration with Brain Iron Accumulation. American journal of human genetics 2018;102(2):266–277.
    OpenUrl
  58. 58.↵
    Bagyinszky E, Youn YC, An SS, Kim S. The genetics of Alzheimer’s disease. Clinical interventions in aging 2014;9:535–551.
    OpenUrlCrossRefPubMed
  59. 59.↵
    Lippa CF, Fujiwara H, Mann DM, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. The American journal of pathology 1998;153(5):1365–1370.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    Deaton CA, Johnson GVW. Presenilin 1 Regulates Membrane Homeostatic Pathways that are Dysregulated in Alzheimer’s Disease. Journal of Alzheimer’s disease : JAD 2020.
  61. 61.↵
    Gatto EM, Rojas GJ, Nemirovsky SI, et al. A novel mutation in PSEN1 (p.Arg41Ser) in an Argentinian woman with early onset Parkinsonism. Parkinsonism & related disorders 2020;77:21–25.
    OpenUrl
  62. 62.↵
    Ravanidis S, Bougea A, Papagiannakis N, et al. Validation of differentially expressed brain-enriched microRNAs in the plasma of PD patients. Annals of clinical and translational neurology 2020.
  63. 63.↵
    Abramzon YA, Fratta P, Traynor BJ, Chia R. The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Frontiers in neuroscience 2020;14:42.
    OpenUrl
  64. 64.
    Doxakis E. RNA binding proteins: a common denominator of neuronal function and dysfunction. Neuroscience bulletin 2014;30(4):610–626.
    OpenUrl
  65. 65.
    Egorova PA, Bezprozvanny IB. Molecular Mechanisms and Therapeutics for Spinocerebellar Ataxia Type 2. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2019;16(4):1050–1073.
    OpenUrl
  66. 66.
    Ravanidis S, Doxakis E. RNA-Binding Proteins Implicated in Mitochondrial Damage and Mitophagy. Frontiers in cell and developmental biology 2020;8:372.
    OpenUrl
  67. 67.
    Ravanidis S, Kattan FG, Doxakis E. Unraveling the Pathways to Neuronal Homeostasis and Disease: Mechanistic Insights into the Role of RNA-Binding Proteins and Associated Factors. International journal of molecular sciences 2018;19(8).
  68. 68.
    Salcedo-Arellano MJ, Dufour B, McLennan Y, Martinez-Cerdeno V, Hagerman R. Fragile X syndrome and associated disorders: Clinical aspects and pathology. Neurobiology of disease 2020;136:104740.
    OpenUrl
  69. 69.
    Kim JM, Hong S, Kim GP, et al. Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. Archives of neurology 2007;64(10):1510–1518.
    OpenUrlCrossRefPubMedWeb of Science
  70. 70.
    Wang C, Xu Y, Feng X, et al. Linkage analysis and whole-exome sequencing exclude extra mutations responsible for the parkinsonian phenotype of spinocerebellar ataxia-2. Neurobiology of aging 2015;36(1):545 e541–547.
    OpenUrl
  71. 71.
    Gwinn-Hardy K, Chen JY, Liu HC, et al. Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology 2000;55(6):800–805.
    OpenUrlCrossRefPubMed
  72. 72.↵
    Furtado S, Payami H, Lockhart PJ, et al. Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Movement disorders : official journal of the Movement Disorder Society 2004;19(6):622–629.
    OpenUrl
  73. 73.↵
    Martens LH, Zhang J, Barmada SJ, et al. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. The Journal of clinical investigation 2012;122(11):3955–3959.
    OpenUrlCrossRefPubMedWeb of Science
  74. 74.
    Piscopo P, Grasso M, Fontana F, et al. Reduced miR-659-3p Levels Correlate with Progranulin Increase in Hypoxic Conditions: Implications for Frontotemporal Dementia. Frontiers in molecular neuroscience 2016;9:31.
    OpenUrl
  75. 75.
    Rademakers R, Eriksen JL, Baker M, et al. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human molecular genetics 2008;17(23):3631–3642.
    OpenUrlCrossRefPubMedWeb of Science
  76. 76.
    Xu J, Xilouri M, Bruban J, et al. Extracellular progranulin protects cortical neurons from toxic insults by activating survival signaling. Neurobiology of aging 2011;32(12):2326 e2325–2316.
    OpenUrl
  77. 77.↵
    Yin F, Banerjee R, Thomas B, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. The Journal of experimental medicine 2010;207(1):117–128.
    OpenUrlAbstract/FREE Full Text
  78. 78.↵
    Bucher M, Fanutza T, Mikhaylova M. Cytoskeletal makeup of the synapse: Shaft versus spine. Cytoskeleton 2020;77(3-4):55–64.
    OpenUrl
  79. 79.
    Pinho J, Marcut C, Fonseca R. Actin remodeling, the synaptic tag and the maintenance of synaptic plasticity. IUBMB life 2020;72(4):577–589.
    OpenUrl
  80. 80.
    Rai SN, Dilnashin H, Birla H, et al. The Role of PI3K/Akt and ERK in Neurodegenerative Disorders. Neurotoxicity research 2019;35(3):775–795.
    OpenUrl
  81. 81.↵
    Santo EE, Paik J. FOXO in Neural Cells and Diseases of the Nervous System. Current topics in developmental biology 2018;127:105–118.
    OpenUrl
  82. 82.↵
    Junqueira SC, Centeno EGZ, Wilkinson KA, Cimarosti H. Post-translational modifications of Parkinson’s disease-related proteins: Phosphorylation, SUMOylation and Ubiquitination. Biochimica et biophysica acta Molecular basis of disease 2019;1865(8):2001–2007.
    OpenUrl
  83. 83.↵
    Pajarillo E, Rizor A, Lee J, Aschner M, Lee E. The role of posttranslational modifications of alpha-synuclein and LRRK2 in Parkinson’s disease: Potential contributions of environmental factors. Biochimica et biophysica acta Molecular basis of disease 2019;1865(8):1992–2000.
    OpenUrl
  84. 84.↵
    Calogero AM, Mazzetti S, Pezzoli G, Cappelletti G. Neuronal microtubules and proteins linked to Parkinson’s disease: a relevant interaction? Biological chemistry 2019;400(9):1099–1112.
    OpenUrl
  85. 85.↵
    Pellegrini L, Wetzel A, Granno S, Heaton G, Harvey K. Back to the tubule: microtubule dynamics in Parkinson’s disease. Cellular and molecular life sciences : CMLS 2017;74(3):409–434.
    OpenUrl
Back to top
Posted November 16, 2020.
Download PDF
Data/Code
Email
Differentially expressed circular RNAs in peripheral blood mononuclear cells of PD patients
Stylianos Ravanidis, Anastasia Bougea, Dimitra Karampatsi, Nikolaos Papagiannakis, Matina Maniati, Leonidas Stefanis, Epaminondas Doxakis
medRxiv 2020.11.14.20231779; doi: https://doi.org/10.1101/2020.11.14.20231779
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area